Cognitively-Based Compassion Training versus cancer health education to improve health-related quality of life in survivors of solid tumor cancers and their informal caregivers: study protocol for a randomized controlled pilot trial

Thaddeus W W Pace, Sally E Dodds, Alla Sikorskii, Terry A Badger, Chris Segrin, Lobsang Tenzin Negi, Timothy Harrison, Tracy E Crane, Thaddeus W W Pace, Sally E Dodds, Alla Sikorskii, Terry A Badger, Chris Segrin, Lobsang Tenzin Negi, Timothy Harrison, Tracy E Crane

Abstract

Background: Cancer survivors and their informal caregivers (family members, close friends) often experience significant impairments in health-related quality of life (HRQOL), including disruptions in psychological, physical, social, and spiritual well-being both during and after primary cancer treatment. The purpose of this in-progress pilot trial is to determine acceptability and preliminary efficacy (as reflected by effect sizes) of CBCT® (Cognitively-Based Compassion Training) compared with a cancer health education (CHE) attention control to improve the primary outcome of depressive symptoms and secondary outcomes of other HRQOL domains (e.g., anxiety, fatigue), biomarkers of inflammation and diurnal cortisol rhythm, and healthcare utilization-related outcomes in both cancer survivors and informal caregivers.

Methods: Forty dyads consisting of solid tumor survivors who have completed primary treatments (chemotherapy, radiation, surgery) and their informal caregivers, with at least one dyad member with ≥ mild depressive symptoms or anxiety, will be recruited from Tucson, Arizona, USA. Survivor-caregiver dyads will be randomized together to complete either CBCT or CHE. CBCT is a manualized, 8-week, group meditation-based intervention that starts with attention and mindfulness and builds to contemplative practices aimed at cultivating compassion to the self and others. The goal of CBCT is to challenge unexamined assumptions about feelings and behaviors, with a focus on generating spontaneous self-compassion and increased empathic responsiveness and compassion for others. CHE is an 8-week, manualized group intervention that provides cancer-specific education on various topics (e.g., cancer advocacy, survivorship wellness). Patient-reported HRQOL outcomes will be assessed before, immediately after (week 9), and 1 month after CBCT or CHE (week 13). At the same time points, stress-related biomarkers of inflammation (e.g., plasma interleukin-6) and saliva cortisol relevant for survivor and informal caregiver wellness and healthcare utilization will be measured.

Discussion: If CBCT shows acceptability, a larger trial will be warranted and appropriately powered to formally test the efficacy of this dyadic intervention. Interventions such as CBCT directed toward both survivors and caregivers may eventually fill a gap in supportive oncology care programs to improve HRQOL and healthcare utilization in both dyad members.

Trial registration: Clinicaltrials.gov, NCT03459781 . Prospectively registered on 9 March 2018.

Keywords: Active control; Cancer survivorship; Compassion meditation; Cortisol; Dyadic interdependence; Health-related quality of life; Inflammation.

Conflict of interest statement

Ethics approval and consent to participate

This study was reviewed and approved by the Institutional Review Board responsible for human subject research at The University of Arizona.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Diagram of study flow. CBCT® Cognitively-Based Compassion Training, CHE cancer health education
Fig. 2
Fig. 2
Study schedule of events. *Primary outcome. CBCT® Cognitively-Based Compassion Training, CHE cancer health education, IL interleukin, NF-κB nuclear factor-κB, PBMC peripheral blood mononuclear cell, TNF tumor necrosis factor

References

    1. NCI. SEER cancer statistics review (CSR) 1975–2014. 2017; . Accessed 1 May 2018, 2015.
    1. Tung HY, Chao TB, Lin YH, Wu SF, Lee HY, Ching CY, Hung KW, Lin TJ. Depression, fatigue, and QoL in colorectal cancer patients during and after treatment. West J Nurs Res. 2016;38(7):893–908. doi: 10.1177/0193945916630256.
    1. Watts S, Leydon G, Birch B, Prescott P, Lai L, Eardley S, Lewith G. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open. 2014;4(3):e003901. doi: 10.1136/bmjopen-2013-003901.
    1. Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, Gralow J. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry. 2008;30(2):112–126. doi: 10.1016/j.genhosppsych.2007.10.008.
    1. Krebber AM, Buffart LM, Kleijn G, Riepma IC, de Bree R, Leemans CR, Becker A, Brug J, van Straten A, Cuijpers P, Verdonck-de Leeuw IM. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 2014;23(2):121–130. doi: 10.1002/pon.3409.
    1. Schneider EC, Malin JL, Kahn KL, Ko CY, Adams J, Epstein AM. Surviving colorectal cancer: patient-reported symptoms 4 years after diagnosis. Cancer. 2007;110(9):2075–2082. doi: 10.1002/cncr.23021.
    1. Colloca G, Venturino A, Governato I, Checcaglini F. Incidence and correlates of fatigue in metastatic castration-resistant prostate cancer: a systematic review. Clin Genitourin Cancer. 2016;14(1):5–11. doi: 10.1016/j.clgc.2015.07.023.
    1. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12(Suppl 1):4–10. doi: 10.1634/theoncologist.12-S1-4.
    1. Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr. 2004;32:40–50. doi: 10.1093/jncimonographs/lgh027.
    1. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vogelzang NJ. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist. 2000;5(5):353–360. doi: 10.1634/theoncologist.5-5-353.
    1. Saboonchi F, Petersson LM, Wennman-Larsen A, Alexanderson K, Vaez M. Trajectories of anxiety among women with breast cancer: a proxy for adjustment from acute to transitional survivorship. J Psychosoc Oncol. 2015;33(6):603–619. doi: 10.1080/07347332.2015.1082165.
    1. Maass SW, Roorda C, Berendsen AJ, Verhaak PF, de Bock G. The prevalence of long-term symptoms of depression and anxiety after breast cancer treatment: a systematic review. Maturitas. 2015;82(1):100–108. doi: 10.1016/j.maturitas.2015.04.010.
    1. Eisenberg SA, Kurita K, Taylor-Ford M, Agus DB, Gross ME, Meyerowitz BE. Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors. Psychooncology. 2015;24(2):228–235. doi: 10.1002/pon.3590.
    1. Lowery AE, Krebs P, Coups EJ, Feinstein MB, Burkhalter JE, Park BJ, Ostroff JS. Impact of symptom burden in post-surgical non-small cell lung cancer survivors. Support Care Cancer. 2014;22(1):173–180. doi: 10.1007/s00520-013-1968-3.
    1. Custers JA, Gielissen MF, Janssen SH, de Wilt JH, Prins JB. Fear of cancer recurrence in colorectal cancer survivors. Support Care Cancer. 2016;24(2):555–562. doi: 10.1007/s00520-015-2808-4.
    1. Braamse AM, van Turenhout ST, Terhaar Sive Droste JS, de Groot GH, van der Hulst RW, Klemt-Kropp M, Kuiken SD, Loffeld RJ, Uiterwaal MT, Mulder CJ, Dekker J. Factors associated with anxiety and depressive symptoms in colorectal cancer survivors. Eur J Gastroenterol Hepatol. 2016;28(7):831–835. doi: 10.1097/MEG.0000000000000615.
    1. Lambert SD, Girgis A, Lecathelinais C, Stacey F. Walking a mile in their shoes: anxiety and depression among partners and caregivers of cancer survivors at 6 and 12 months post-diagnosis. Support Care Cancer. 2013;21(1):75–85. doi: 10.1007/s00520-012-1495-7.
    1. Cubukcu M. Evaluation of quality of life in caregivers who are providing home care to cancer patients. Support Care Cancer. 2018;26(5):1457–1463.
    1. Kent EE, Rowland JH, Northouse L, Litzelman K, Chou WY, Shelburne N, Timura C, O’Mara A, Huss K. Caring for caregivers and patients: research and clinical priorities for informal cancer caregiving. Cancer. 2016;122(13):1987–1995. doi: 10.1002/cncr.29939.
    1. Northouse L, McCorkle R. Spouse caregivers of cancer patients. In: Holland JCBW, Butow PN, Jacobsen PB, Loscalzo MJ, McCorkle R, editors. Psycho-oncology. 3. New York: Oxford University Press; 2015. pp. 567–578.
    1. Litzelman Kristin, Kent Erin E., Mollica Michelle, Rowland Julia H. How Does Caregiver Well-Being Relate to Perceived Quality of Care in Patients With Cancer? Exploring Associations and Pathways. Journal of Clinical Oncology. 2016;34(29):3554–3561. doi: 10.1200/JCO.2016.67.3434.
    1. Sherwood PR, Price TJ, Weimer J, Ren D, Donovan HS, Given CW, Given BA, Schulz R, Prince J, Bender C, Boele FW, Marsland AL. Neuro-oncology family caregivers are at risk for systemic inflammation. J Neuro-Oncol. 2016;128(1):109–118. doi: 10.1007/s11060-016-2083-3.
    1. Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci U S A. 2003;100(15):9090–9095. doi: 10.1073/pnas.1531903100.
    1. Schulz R, Sherwood PR. Physical and mental health effects of family caregiving. Am J Nurs. 2008;108(9 Suppl):23–27. doi: 10.1097/01.NAJ.0000336406.45248.4c.
    1. Segrin C, Badger TA. Psychological and physical distress are interdependent in breast cancer survivors and their partners. Psychol Health Med. 2014;19(6):716–723. doi: 10.1080/13548506.2013.871304.
    1. Segrin C, Badger TA, Harrington J. Interdependent psychological quality of life in dyads adjusting to prostate cancer. Health Psychol. 2012;31(1):70–79. doi: 10.1037/a0025394.
    1. Hatfield E, Cacioppo JT, Rapson RL. Emotional contagion. Cambridge: Cambridge University Press; 1994.
    1. Ozawa-de Silva B, Negi LT. Cognitively-Based Compassion Training (CBCT): protocol and key concepts. In: Singer T, Bolz M, editors. Compassion: bridging practice and science. Munich: Max Planck Society; 2013. pp. 416–438.
    1. Ozawa-de Silva B, Dodson-Lavelle B. Education of heart and mind: practical and theoretical issues in teaching Cognitively-Based Compassion Training to children. Practial Matters. 2011;4:1–28.
    1. Dodds SE, Pace TWW, Bell ML, Fiero M, Negi LT, Raison CL, Weihs KL. Feasibility of Cognitively-Based Compassion Training (CBCT) for breast cancer survivors: a randomized, wait list controlled pilot study. Support Care Cancer. 2015;23(12):3599–3608. doi: 10.1007/s00520-015-2888-1.
    1. Mascaro JS, Rilling JK, Tenzin Negi L, Raison CL. Compassion meditation enhances empathic accuracy and related neural activity. Soc Cogn Affect Neurosci. 2013;8(1):48–55. doi: 10.1093/scan/nss095.
    1. Pace TWW, Negi LT, Dodson-Lavelle B, Ozawa-de Silva B, Reddy SD, Cole SP, Danese A, Craighead LW, Raison CL. Engagement with Cognitively-Based Compassion Training is associated with reduced salivary C-reactive protein from before to after training in foster care program adolescents. Psychoneuroendocrinology. 2013;38(2):294–299. doi: 10.1016/j.psyneuen.2012.05.019.
    1. Reddy SD, Negi LT, Dodson-Lavelle B, Ozawa-de Silva B, Pace TWW, Cole SP, Raison CL, Craighead LW. Cognitively-based Compassion Training: a promising prevention strategy for at-risk adolescents. J Child Fam Stud. 2012;22(2):219–230. doi: 10.1007/s10826-012-9571-7.
    1. Desbordes G, Negi LT, Pace TWW, Wallace BA, Raison CL, Schwartz EL. Effects of mindful-attention and compassion meditation training on amygdala response to emotional stimuli in an ordinary, non-meditative state. Front Hum Neurosci. 2012;6:292. doi: 10.3389/fnhum.2012.00292.
    1. Pace TWW, Negi LT, Sivilli TI, Issa MJ, Cole SP, Adame DD, Raison CL. Innate immune, neuroendocrine and behavioral responses to psychosocial stress do not predict subsequent compassion meditation practice time. Psychoneuroendocrinology. 2010;35(2):310–315. doi: 10.1016/j.psyneuen.2009.06.008.
    1. Pace TWW, Negi LT, Adame DD, Cole SP, Sivilli TI, Brown TD, Issa MJ, Raison CL. Effect of compassion meditation on neuroendocrine, innate immune and behavioral responses to psychosocial stress. Psychoneuroendocrinology. 2009;34(1):87–98. doi: 10.1016/j.psyneuen.2008.08.011.
    1. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–56. doi: 10.1038/nrn2297.
    1. Bower JE. Cancer-related fatigue—mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11(10):597–609. doi: 10.1038/nrclinonc.2014.127.
    1. Cheruvu VK, Oancea SC. Current depression as a potential barrier to health care utilization in adult cancer survivors. Cancer Epidemiol. 2016;44:132–137. doi: 10.1016/j.canep.2016.08.012.
    1. Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, Amtmann D, Bode R, Buysse D, Choi S, Cook K, Devellis R, DeWalt D, Fries JF, Gershon R, Hahn EA, Lai JS, Pilkonis P, Revicki D, Rose M, Weinfurt K, Hays R. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010;63(11):1179–1194. doi: 10.1016/j.jclinepi.2010.04.011.
    1. Pulos S, Elison J, Lennon R. The hierarchical structure of the Interpersonal Reactivity Index. Soc Behav Pers. 2004;32:355–359. doi: 10.2224/sbp.2004.32.4.355.
    1. Davis MH. Measuring individual differences in empahty: evidence for a multi-dimensional approach. J Pers Soc Psychol. 1983;44:113–126. doi: 10.1037/0022-3514.44.1.113.
    1. Davis MH. Empathy: a social psychological approach. Boulder: Westview Press; 1994.
    1. Lee RM, Draper M, Lee S. Social connectedness, dysfunctional interpersonal behaviors, and psychological distress: testing a mediator model. J Couns Psychol. 2001;48(3):310–318. doi: 10.1037/0022-0167.48.3.310.
    1. Ferrans CE, Powers M. Ferrans and Powers Quality of Life Index (QLI): reliability and validity. [website]. . Accessed 1 June 2018.
    1. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988;54(6):1063–1070. doi: 10.1037/0022-3514.54.6.1063.
    1. Hendrick SS. A generic measure of relationship satisfaction. J Marriage Fam. 1988;50:93–98. doi: 10.2307/352430.
    1. Neff KD. Development and validation of a scale to measure self-compassion. Self Identity. 2003;2:223–250. doi: 10.1080/15298860309027.
    1. Breines JG, Thoma MV, Gianferante D, Hanlin L, Chen X, Rohleder N. Self-compassion as a predictor of interleukin-6 response to acute psychosocial stress. Brain Behav Immun. 2014;37:109–114. doi: 10.1016/j.bbi.2013.11.006.
    1. Lorig KR, Sobel DS, Ritter PL, Laurent D, Hobbs M. Effect of a self-management program on patients with chronic disease. Eff Clin Pract. 2001;4(6):256–262.
    1. Kirchhoff AC, Lyles CR, Fluchel M, Wright J, Leisenring W. Limitations in health care access and utilization among long-term survivors of adolescent and young adult cancer. Cancer. 2012;118(23):5964–5972. doi: 10.1002/cncr.27537.
    1. Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004;39(4 Pt 1):1005–1026. doi: 10.1111/j.1475-6773.2004.00269.x.
    1. Hibbard JH, Mahoney ER, Stockard J, Tusler M. Development and testing of a short form of the patient activation measure. Health Serv Res. 2005;40(6 Pt 1):1918–1930. doi: 10.1111/j.1475-6773.2005.00438.x.
    1. Quinn Andrea M., Williams Allison R., Sivilli Teresa I., Raison Charles L., Pace Thaddeus W. W. The plasma interleukin-6 response to acute psychosocial stress in humans is detected by a magnetic multiplex assay: comparison to high-sensitivity ELISA. Stress. 2018;21(4):376–381. doi: 10.1080/10253890.2018.1446518.
    1. Torres MA, Pace TWW, Liu T, Felger JC, Mister D, Doho GH, Kohn JN, Barsevick AM, Long Q, Miller AH. Predictors of depression in breast cancer patients treated with radiation: role of prior chemotherapy and nuclear factor kappa B. Cancer. 2014;119(11):1951–1959. doi: 10.1002/cncr.28003.
    1. Pace TWW, Wingenfeld K, Schmidt I, Meinlschmidt G, Hellhammer DH, Heim CM. Increased peripheral NF-kappaB pathway activity in women with childhood abuse-related posttraumatic stress disorder. Brain Behav Immun. 2012;26(1):13–17. doi: 10.1016/j.bbi.2011.07.232.
    1. Pace TWW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH, Heim CM. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry. 2006;163(9):1630–1633. doi: 10.1176/ajp.2006.163.9.1630.
    1. Negi LT. Emory compassion meditation protocol: Cognitively-Based Compassion Training manual. Atlanta: Emory University; 2013.
    1. Ozawa-de Silva B, Dodson-Lavelle B, Raison CL, Negi LT. Compassion and ethics: scientific approaches to the cultivation of compassion as a foundation for ethical subjectivity and well-being. J Healthcare Sci Human. 2012;11(1):145–157.
    1. Badger TA, Segrin C, Figueredo AJ, Harrington J, Sheppard K, Passalacqua S, Pasvogel A, Bishop M. Psychosocial interventions to improve quality of life in prostate cancer survivors and their intimate or family partners. Qual Life Res. 2011;20(6):833–844. doi: 10.1007/s11136-010-9822-2.
    1. Badger TA, Segrin C, Hepworth JT, Pasvogel A, Weihs K, Lopez AM. Telephone-delivered health education and interpersonal counseling improve quality of life for Latinas with breast cancer and their supportive partners. Psychooncology. 2013;22(5):1035–1042. doi: 10.1002/pon.3101.
    1. Cella D, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) study 5592. J Clin Epidemiol. 2002;55(3):285–295. doi: 10.1016/S0895-4356(01)00477-2.
    1. Sloan JA, Cella D, Hays RD. Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol. 2005;58(12):1217–1219. doi: 10.1016/j.jclinepi.2005.07.009.
    1. Segrin C, Badger TA, Sikorskii A, Crane TE, Pace TWW. A dyadic analysis of stress processes in Latinas with breast cancer and their family caregivers. Psychooncology. 2018;27(3):838–846. doi: 10.1002/pon.4580.
    1. Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008;26(6):971–982. doi: 10.1200/JCO.2007.10.7805.
    1. Collado-Hidalgo A, Bower JE, Ganz PA, Irwin MR, Cole SW. Cytokine gene polymorphisms and fatigue in breast cancer survivors: early findings. Brain Behav Immun. 2008;22(8):1197–1200. doi: 10.1016/j.bbi.2008.05.009.
    1. Bower JE. Prevalence and causes of fatigue after cancer treatment: the next generation of research. J Clin Oncol. 2005;23(33):8280–8282. doi: 10.1200/JCO.2005.08.008.
    1. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2002;64(4):604–611. doi: 10.1097/00006842-200207000-00010.
    1. Bower JE, Ganz PA, Tao ML, Hu W, Belin TR, Sepah S, Cole S, Aziz N. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin Cancer Res. 2009;15(17):5534–5540. doi: 10.1158/1078-0432.CCR-08-2584.
    1. Wratten C, Kilmurray J, Nash S, Seldon M, Hamilton CS, O’Brien PC, Denham JW. Fatigue during breast radiotherapy and its relationship to biological factors. Int J Radiat Oncol Biol Phys. 2004;59(1):160–167. doi: 10.1016/j.ijrobp.2003.10.008.
    1. Collado-Hidalgo A, Bower JE, Ganz PA, Cole SW, Irwin MR. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res. 2006;12(9):2759–2766. doi: 10.1158/1078-0432.CCR-05-2398.
    1. Musselman DL. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatr. 2001;158(8):1252–1257. doi: 10.1176/appi.ajp.158.8.1252.
    1. Marsland AL, Walsh C, Lockwood K, John-Henderson NA. The effects of acute psychological stress on circulating and stimulated inflammatory markers: a systematic review and meta-analysis. Brain Behav Immun. 2017;64:208–219. doi: 10.1016/j.bbi.2017.01.011.
    1. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171–186. doi: 10.1097/PSY.0b013e3181907c1b.
    1. Miller GE, Murphy ML, Cashman R, Ma R, Ma J, Arevalo JM, Kobor MS, Cole SW. Greater inflammatory activity and blunted glucocorticoid signaling in monocytes of chronically stressed caregivers. Brain Behav Immun. 2014;41:191–199. doi: 10.1016/j.bbi.2014.05.016.
    1. Bower JE, Ganz PA, Irwin MR, Arevalo JM, Cole SW. Fatigue and gene expression in human leukocytes: increased NF-kappaB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain Behav Immun. 2011;25(1):147–150. doi: 10.1016/j.bbi.2010.09.010.
    1. Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. Soc Biol Psychiatry. 2003;54:269–282. doi: 10.1016/S0006-3223(03)00566-3.
    1. Spiegel D, Giese-Davis J, Taylor CB, Kraemer H. Stress sensitivity in metastatic breast cancer: analysis of hypothalamic-pituitary-adrenal axis function. Psychoneuroendocrinology. 2006;31(10):1231–1244. doi: 10.1016/j.psyneuen.2006.09.004.
    1. Giese-Davis J, Spiegel D. Emotional expression and cancer progression. In: Davidson RJ, Scherer K, Hill Goldsmith H, eds. Series in affective science. Handbook of affective sciences. New York, NY: Oxford University Press; 2003:1053–1082.
    1. Giese-Davis J, Wilhelm FH, Conrad A, Abercrombie HC, Sephton S, Yutsis M, Neri E, Taylor CB, Kraemer HC, Spiegel D. Depression and stress reactivity in metastatic breast cancer. Psychosom Med. 2006;68(5):675–683. doi: 10.1097/01.psy.0000238216.88515.e5.
    1. Giese-Davis J, Collie, et al. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol. 2010;29(4):413–420. doi: 10.1200/JCO.2010.28.4455.
    1. Bower JE, Ganz PA, Dickerson SS, Peterson L, Azia N, Fahey JL. Diurnal cortisol rhythm and fatigue in breast cancer survivors. PsychoNeuroendocrinology. 2005;30:92–100. doi: 10.1016/j.psyneuen.2004.06.003.
    1. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92(12):994–1000. doi: 10.1093/jnci/92.12.994.
    1. Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol. 2008;5(8):466–475. doi: 10.1038/ncponc1134.
    1. Jarcho MR, Slavich GM, Tylova-Stein H, Wolkowitz OM, Burke HM. Dysregulated diurnal cortisol pattern is associated with glucocorticoid resistance in women with major depressive disorder. Biol Psychol. 2013;93(1):150–158. doi: 10.1016/j.biopsycho.2013.01.018.
    1. Spiegel D, Giese-Davis J, Taylor CB, Kraemer H. Stress sensitivity in metastatic breast cancer: analysis of the hypothalmic-pituitary-adrenal axis function. PsychoNeuroendocrinology. 2006;31:1231–1244. doi: 10.1016/j.psyneuen.2006.09.004.
    1. Giese-Davis J, Sephton SE, Abercrombie HC, Duran RE, Spiegel D. Repression and high anxiety are associated with aberrant diurnal cortisol rhythms in women with metastatic breast cancer. Health Psychol. 2004;23(6):645–650. doi: 10.1037/0278-6133.23.6.645.
    1. Abercrombie HC, Giese-Davis J, Sephton S, Epel ES, Turner-Cobb JM, Spiegel D. Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology. 2004;29(8):1082–1092. doi: 10.1016/j.psyneuen.2003.11.003.
    1. Turner-Cobb JM, Sephton SE, Koopman C, Blake-Mortimer J, Spiegel D. Social support and salivary cortisol in women with metastatic breast cancer. Psychosom Med. 2000;62(3):337–345. doi: 10.1097/00006842-200005000-00007.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi